In conclusion, the results of the present study support the use of DPSCs as a source of secretome which is highly enriched in neurotrophic factors, Aβ-degrading enzyme (NEP), and antiapoptotic factors, rendering DPSCs promising candidates for secretome-based therapy for AD providing a novel therapeutic approach against one of the most common neurodegenerative diseases. This evidence concerns the gene MME and neurodegenerative disease.